Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 6 Months Ended
Apr. 30, 2019
Apr. 30, 2018
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (7,541,543) $ (3,257,988)
Stock option compensation to employees and directors 2,024,664 472,532
Stock options and warrants issued to consultants 92,509 126,151
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441
Common stock issued to consultants 15,002
Depreciation of property and equipment 18,108 7,369
Amortization of patents 376,875 162,648
Impairment in carrying amount of patent assets 418,750
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Receivables (489,963) (41,889)
Prepaid expenses and other current assets 51,219 (81,726)
Accounts payable 135,908 (28,218)
Accrued expenses 194,742 478,982
Net cash used in operating activities (2,764,290) (2,082,481)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (1,000,000) (1,250,000)
Proceeds from maturities of short-term investments in certificates of deposit 250,000 3,500,000
Purchase of property and equipment (175,457) (11,813)
Net cash (used in) provided by investing activities (925,457) 2,238,187
Cash flows from financing activities:    
Net proceeds from sale of common stock in at-the-market offering 4,357,803 677,370
Proceeds from sale of common stock pursuant to employee stock purchase plan 18,560
Proceeds from exercise of employee stock options 79,800
Net cash provided by financing activities 4,456,163 677,370
Net increase in cash and cash equivalents 766,416 833,076
Cash and cash equivalents at beginning of period 3,055,890 3,339,374
Cash and cash equivalents at end of period $ 3,822,306 $ 4,172,450